Sendas Distribuidora (Assaí): Deleveraging Done Well, Growth Too Slow To Upgrade

Assaí Atacadista — the cash-and-carry retail chain operating under Sendas Distribuidora on Brazil's B3 exchange — delivered a second quarter that reads as financial discipline rather than a growth story. Recurring net income nearly doubled, leverage fell to its lowest level since late 2021, and free cash flow generation remains robust. The problem is that the top line is barely growing in a sluggish Brazilian consumer environment, and management has paused store expansion until the balance sheet heals. The valuation has adjusted to reflect this patience. The question is whether it has adjusted enough.

My rating: Hold. The deleveraging path is real, and the multiples are compressed. But same-store sales of under 1% and a frozen expansion plan mean there is no near-term catalyst for multiple expansion. The stock is a Buy only if same-store sales reaccelerate or the balance sheet improves enough to restart store openings ahead of the market's timeline.

What the quarter actually shows

Gross revenue reached R$21.4 billion in Q2 2026, up 2.4% year-over-year. Net revenue grew a more modest 0.9% to R$19.2 billion. Gross margin expanded 0.4 percentage points to 17.1%, helped by private label initiatives and cost discipline. EBITDA margin (earnings before interest, taxes, depreciation, and amortization — a proxy for operating cash generation) held flat at roughly 5.6%. This margin profile tells the story: Assaí is gaining scale and efficiency, but it is not winning a pricing war. Brazilian consumers are trading down to the cash-and-carry format, but they're still price-sensitive, and Assaí's competitive position in that format limits its ability to raise prices.

The profit surge is the quarter's headline. Recurring net income climbed to R$344 million, a 94% jump from a year earlier. Accounting net income reached R$537 million, though that figure includes non-recurring tax credits and should be treated with some skepticism. The real driver of the profit increase is not revenue growth — it's financial leverage working in the opposite direction. Financial expenses fell 5% year-over-year, and the company is generating enough cash to service and reduce its debt. That's a mechanical improvement, not a growth reacceleration.

The balance sheet is the story

This is where the quarter actually justifies investor attention. Financial leverage dropped to 2.37x EBITDA, down 0.8x from the prior year, marking the lowest level since the third quarter of 2021. Net debt decreased by R$1.4 billion year-over-year. Operating cash flow over the last 12 months reached R$3.3 billion, with free cash flow of R$2.7 billion. The gross cash position stands at R$7 billion, up 20.9% year-over-year, covering two full years of debt maturities.

Management has been explicit: deleveraging is the priority. New store openings are paused with no firm timeline for resumption. The 2026 store guidance was cut to just 5 openings. The R$700 million investment plan focuses on existing-store productivity — digital infrastructure, private label development, and the pharmacy initiative — rather than footprint expansion. CFO Rafael Sachete described the cash position as "very solid" on the earnings call, and the numbers back that up. This is not a company that needs to raise capital or refinance under stress.

Where growth actually lives

The cash-and-carry model — bulk retail targeting price-sensitive households and small businesses — is gaining share in Brazil, and Assaí is capturing it. Customer traffic now exceeds 40 million monthly visits, up 3.4% year-over-year. Market share in the cash-and-carry segment increased 0.3 percentage points. Same-store sales grew 0.9% in Q2 and 0.5% in July, both measured on a constant-currency basis excluding calendar effects. These are positive but unspectacular numbers in a consumer environment where 82% of household income is committed to debt service.

The more interesting growth vectors are the low-capital initiatives that management has been touting. Assaí Farma, the in-store pharmacy program, opened its first two units in São Paulo with early results that exceeded internal expectations. The capital expenditure per pharmacy unit is under R$400,000, with a total estimated investment of R$100 million for a 250-unit network. That's a high-return use of capital if execution holds. Private label products have expanded to 30 SKUs, with targets of 250 by year-end and 500+ in 2027. Self-checkout volumes rose 40% year-over-year, contributing to labor cost reduction. The iFood delivery partnership now covers 104 stores, with last-mile sales up 237%. These initiatives are real, but they are still small relative to the R$77.6 billion annual revenue base. Even if all of them hit plan, the incremental contribution to 2027 earnings would be incremental, not transformative.

Valuation: compressed, but not cheap enough for a blind bid

Assaí trades at roughly 5.2x EV/EBITDA and about 11.5x trailing earnings, with a market cap near BRL 11.4 billion and enterprise value around BRL 23 billion. The stock sits approximately 18% below its 52-week high of R$297 per share, having pulled back from that peak as the growth narrative cooled and the expansion pause became clear.

The 5.2x EV/EBITDA multiple is undeniably compressed. For a business generating R$2.7 billion in free cash flow annually, that's an EV-to-free-cash-flow ratio of roughly 8.5x. Those are numbers that suggest the market has already priced in a prolonged period of sub-5% revenue growth and limited margin expansion. The multiple gives Assaí room to execute on its deleveraging plan without the stock needing to tell a growth story to justify its price.

But compressed is not the same as bargain. The EV/EBITDA multiple is attractive only if leverage continues its descent toward management's 2.0x target and same-store sales hold above the 0.5% level currently being seen. If the Brazilian consumer deteriorates further — higher debt burdens, more aggressive trade-down to informal retail, or a currency shock — the low-margin cash-and-carry model would feel the pain first. At 5.6% EBITDA margin, there is not much cushion.

What would change the rating

An upgrade to Buy requires one of three things. First, same-store sales need to reaccelerate above 2-3%, showing that traffic gains are converting into basket-size growth, not just substitution. Second, leverage needs to fall to around 2.0x, at which point store expansion can restart and the market will reward the growth optionality. Management has given no timeline for either. Third, the pharmacy and private label initiatives need to demonstrate material contribution to margins — not just early promise, but actual earnings impact in Q3 or Q4 results.

A downgrade to Avoid would follow if same-store sales turn negative, EBITDA margin compresses below 5%, or the debt reduction path stalls. The consumer data suggests the former is a real risk if the macroeconomic environment worsens.

The investor takeaway

Assaí is executing on the balance sheet while the top line grinds along. That's a legitimate strategy, and the valuation has adjusted to match the patience it requires. The 5.2x EV/EBITDA multiple is defensible for a company cutting debt and holding market share in a weak consumer environment. But defensible is not the same as exciting. This is a Hold until the deleveraging unlocks the next growth phase — and until that happens, the stock's upside is a function of earnings accretion from lower interest costs, not multiple expansion. Watch same-store sales through the September quarter and the pace of leverage reduction. Those two metrics will tell you whether this is a turnaround in progress or a slow-burn balance sheet repair that keeps investors waiting.